目的 探讨药物治疗管理(MTM)中临床药学服务对老年 2 型糖尿病并周围神经炎患者用药有效性、依从性、安全性和经济性的影响.方法 选取 2019 年 5 月至 2020 年 4 月我院内分泌科收治诊断为老年 2 型糖尿病并周围神经炎的患者 120 例,按照随机数字表方法将其分为参照组(n=60)、干预组(n=60).参照组为常规护理干预,干预组则在参照组的基础上使用临床药学服务干预.结果 干预组空腹血糖、餐后 2 h血糖、糖化血红蛋白水平均明显低于参照组(P<0.05);干预组随访后用药依从性管理评分为[(5.96±0.56)分]明显优于参照组[(5.15±0.22)分],差异有统计学意义(P<0.05);干预组不良反应发生率明显低于参照组(P<0.05),药品费用亦明显降低(P<0.05).结论 通过临床药师在MTM中提供临床药学服务干预后,老年 2 型糖尿病并周围神经炎患者在有效性、依从性、安全性、经济性等方面产生有益效果,提高了药物疗效,提高了患者依从性,减少了药物不良反应或事件,降低了药物治疗费用.
Objective To explore the effects of clinical pharmaceutical care in medication therapy management(MTM)on effectiveness,compliance,safety and economy in elderly patients with type 2 diabetes mellitus and peripheral neuritis.Methods A total of 120 elderly patients diagnosed with type 2 diabetes mellitus and peripheral neuritis admitted to the Endocrinology Department of our hospital from May 2019 to April 2020 were selected,and they were divided into control group(n=60)and intervention group(n= 60)according to random number table method.The control group used routine nursing intervention,and the intervention group used clinical pharmaceutical care intervention on the basis of the control group.Results The levels of fasting blood glucose,2h postpran-dial blood glucose and HBA1c in the intervention group were significantly lower than those in the control group(P<0.05).After fol-low-up,the management score of medication compliance in the intervention group[(5.96±0.56)points]was significantly better than that in the control group[(5.15±0.22)points],and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the intervention group was significantly lower than that in the control group(P<0.05),and the drug cost was also significantly reduced(P<0.05).Conclusion After clinical pharmaceutical care intervention provided by clinical pharmacists in MTM,the elder-ly patients with type 2 diabetes mellitus and peripheral neuritis have beneficial effects in terms of effectiveness,compliance,safety and e-conomy,improving drug efficacy,improving patient compliance,re-ducing adverse drug reactions or events,and reducing drug treatment costs.